Study of Semaglutide on Mental Health A study made in 2024, analyzing data from over 3,500 participants across multiple clinical trials found no increased risk of mental health issues among those using semaglutide for weight loss
For tablet applications, consider using acetylated glutathione as an alternative, which offers compression stability though slightly lower bioavailability than liposomes
Others offer minimal medical screening, which can overlook health risks
Which medicines are covered The PAP only covers a specific list of Novo Nordisk registered trademark medicines, which currently includes certain GLP-1 medications (Ozempic, Rybelsus and Xultophy), insulin products (Fiasp, Novolin R, Novolin N and Novolin 70/30, NovoLog Vial, NovoLog PenFill and Flexpen, NovoLog Mix, Tresiba), devices (Novopen, NovoFine), and other selected specialty therapies